Scios Incorporated Company Profile

08:51 EST 20th November 2017 | BioPortfolio

Scios Inc. is a biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of novel human therapeutics based upon its capabilities in both protein-based and small-molecule drug discovery and development. An NDA for the use of Natrecor(R) (nesiritide) for the short-term management of congestive heart failure ispending with the U.S. Food and Drug Administration ("FDA"). On January 29, 1999, the Cardiovascular and Renal Drugs Advisory Committee to the FDA recommended that the FDA approve Natrecor(R) for sale in the United States. Fiblast(R) (trafermin) is in Phase II/III clinical trials in Europe for stroke and the Company plans to do additional Phase II clinical trials for other vascular indications.


820 West Maude Avenue
United States of America


Phone: (408) 616-8200
Fax: 415 968 2438

News Articles [1 Associated News Articles listed on BioPortfolio]

Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the pricing of its underwritten public offering of 14,285,714 shares of common stock or common stock ...

PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult. In th...

Companies [40 Associated Companies listed on BioPortfolio]

Scios Inc

In 2001, Scios Inc. caught international attention with the successful U.S. launch of NATRECOR® (nesiritide), the first new approved treatment for acute heart failure in more than a decade. To date, ...

Scios Inc.

Scios Incorporated

Scios Inc. is a biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of novel human therapeutics based upon its capabilities in both protein-...


PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

Guilford Pharmaceuticals Incorporated

Guilford Pharmaceuticals Inc. was founded in July 1993 by Scios Nova Inc., Dr. Solomon H. Snyder and Dr. Craig R. Smith to discover and develop novel pharmaceutical and biopolymer-based products that ...

More Information about "Scios Incorporated" on BioPortfolio

We have published hundreds of Scios Incorporated news stories on BioPortfolio along with dozens of Scios Incorporated Clinical Trials and PubMed Articles about Scios Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Scios Incorporated Companies in our database. You can also find out about relevant Scios Incorporated Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record